Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Prof Marek Trněný - Charles University, Prague, Czechia
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )
18 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA
STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Jun 2026

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )
10 Jun 2026

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )
10 Jun 2026